New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

There’s rarely good news about Alzheimer’s disease, but a failed study may open the door to more research about vascular ...

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

November is designated as Alzheimer's Disease Awareness Month. It's a time to take a look at what can be done to help loved ...